Congenital errors of metabolism with epileptic seizures during the first years of life;Errores congénitos del metabolismo con crisis epilépticas en los primeros años de vida

Revista de Neurologia

Volumn 35, Issue SUPPL. 1, 2002, Pages

  Campistol, Jaume ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Children; Congenital errors of metabolism; Diagnostic protocol; Epilepsy

Indexed keywords

4 AMINOBUTYRIC ACID; BIOTINIDASE; CARBOHYDRATE; CARBOXYLIC ACID; GLUCOSE; GLYCOPROTEIN; LYSOZYME; MITOCHONDRIAL DNA; NEUROTRANSMITTER; PURINE; PYRIMIDINE; SULFITE OXIDASE;

ADRENOLEUKODYSTROPHY; CHILD; ELECTROENCEPHALOGRAM; ENZYME DEFICIENCY; EPILEPSY; FUCOSIDOSIS; GALACTOSIALIDOSIS; GANGLIOSIDOSIS; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; GLUCOSE TRANSPORT; GM1 GANGLIOSIDOSIS; GM2 GANGLIOSIDOSIS; HISTIDINEMIA; HOMOCYSTINURIA; HUMAN; HYPERAMMONEMIA; HYPERGLYCEMIA; HYPERPROLINEMIA; INBORN ERROR OF METABOLISM; INFANT; LIPOFUSCINOSIS; LYSOSOME STORAGE DISEASE; MELAS SYNDROME; MENKES SYNDROME; MERRF SYNDROME; METACHROMATIC LEUKODYSTROPHY; MUCOPOLYSACCHARIDOSIS; NEURONAL CEROID LIPOFUSCINOSIS; NEUROTRANSMISSION; NIEMANN PICK DISEASE; ONSET AGE; PATHOPHYSIOLOGY; PHENYLKETONURIA; REVIEW; SANDHOFF DISEASE; SEIZURE; SIALIDOSIS; TAY SACHS DISEASE;

AMINO ACIDS; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; ELECTRORETINOGRAPHY; EPILEPSY; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES; ORGANELLES;

EID: 0036764006     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Aicardi J. Diseases of the Nervous System in Childhood. 2 Ed. London: MacKeith Press; 1998.
2. Allen RJ. Degenerative disorders of the central nervous system. The Practice of Pediatric Neurology. Sant Louis: Mosby CV Eds.; 1989.
3. Arthuis M, Pinsard N, Ponsot G. Neurologie Pediatrique. 2 Ed. Paris: Flammarion Medecine Sciences; 1998.
4. Campistol J. Aproximación al diagnóstico de la enfermedades neurometabólicas pot la neuroimagen. Rev Neurol 1999; 28: 16-23.
5. Fernández J, Saudubray JM, van den Berghe G, eds. Clinical Approach to the Inherited Metabolic Diseases. Berlin: Springer Verlag; 1995.
6. Fejerman N, Fernández Álvarez E. Neurología Pediátrica. 2 Ed. Buenos Aires: El Ateneo; 1997.
7. Campistol J. Síndromes epilépticos del período neonatal y errores congénitos del metabolismo. Rev Neurol 2000; 30 (Supl 1): S60-74.
8. Lyon G, Evrard PH. Neuropediatría. Barcelona: Masson; 1990.
9. Cohen BH. Metabolic and degenerative diseases associated with epilepsy. Epilepsia 1993; 34 (Suppl 3): S62-70.
10. Herranz JL, de las Cuevas I. Manifestaciones epilépticas de causa metabólica. Rev Neurol 1999; 28 (Supl 1): S23-8.
11. Valnot I, Ormond S, Gigarel N. Mutations of the SCO 1 gene in mitochondrial cytochrome c oxidase (COX) deficiency with neonatal-onset hepatic failure and encephalopathy. Am J Hum Genet 2000; 67: 1104-9.
12. Wisniewski KE, Zhong N, Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinosis. Neurology 2001; 57: 576-81.
13. Tümer Z, Horn N. Menkes disease: Recent advances and new aspects. J Med Genet 1997; 34: 265-74.
14. Guitet M, Campistol J, Medina M. Enfermedad de Menkes: Experiencia en el tratamiento con sales de cobre. Rev Neurol 1999; 29: 127-30.
15. Taylor RW, Hayes CM, Chinnery PF, Johnson MA, Kler RS, et al. Epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48: 188-93.
16. DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. Am J Med Genet 2001; 10: 18-26.
17. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, et al. Melas: An original case and clinical criteria for diagnosis. Neuromusc Disord 1992; 2: 125-35.
18. Poulton J, Turnbull DM. 74th ENMC International workshop: Mitochondrial diseases. Neuromusc Disord 2000; 10: 460-2.
19. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerget Biomemb 1997; 29: 131-49.
20. Thorburn DR, Dahl HHM. Mitochondrial disorders: Genetics, counseling, prenatal diagnosis and reproductive options. Am J Med Genet 2001; 106: 102-14.
21. Meikle PJ, Hopwood JJ, Claque ME, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
22. Hobbs JR. Displacement bone marrow transplantation for some inborn errors. J Inher Metab Dis 1990; 13: 572-96.
23. Vanier MT, Rousson R. Les sphingolipidoses. Ann Biol Clin 1988; 46: 461-8.
24. Soper BN, Lessard MD, Vogler CA, Levy B, Beamer WG, Sly WS. Nonablative neonatal marrow transplantation attenuates functional and physiological defects of beta-glucuronidase deficiency. Blod 2001; 197: 1498-504.
25. Hagberg B, Kollberg H, Sourander P, Akesson HO Infantile globoid cell leukodystrophy (Krabbe's disease): A clinical and genetic study of 32 Swedish cases 1953-1967. Neuropaediatrie 1970; 1: 74-88.
26. Fu L, Inui K, Nishigaki T, Tatsumi N, Tsukamoto H, Kokubu C, Muramatsu T, Okada S. Molecular heterogeneity of Krabbe disease. J Inherit Metab Dis 1999; 22: 155-62.
27. Loonen MC, van Diggelen OP, Janse HC, Kleijer WJ, Arts WF. Late-onset globoid cell leucodystrophy (Krabbe's disease). Clinical and genetic delineation of two forms and their relation to the early-infantile form. Neuropediatrics 1985; 16: 137-42.
28. Lyon G, Hagberg B, Evrard P, Allaire C, Pavone L, Vanier M. Symptomatology of late onset Krabbe's leukodystrophy: The European experience. Dev Neurosci 1991; 13: 240-4.
29. Verdru P, Lammens M, Dom R, van Elsen A, Carton H. Globoid cell leukodystrophy: A family with both late-infantile and adult type. Neurology 1991; 41: 1382-4.
30. Wenger DA. Krabbe disease (globoid cell leukodystrophy). In Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, eds. The Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth-Heinemann; 1997. p. 421-31.
31. Van Diggelen OP, Schindler D, Kleijer WS. Lysosomal alpha-N-acetylgalactosaminidase deficiency: A new inherited metabolic disease. Lancet 1987; 2: 804.
32. Desnick RJ, Wang AM. Schindler disease: An inherited neuroaxonal dystrophy due to alpha-N-acetylgalaetosaminidase acetylgalactosaminidase Deficiency. J Inher Metab Dis 1990; 13: 549-59.
33. Desnick R, Bishop D. Fabry disease and Schindler disease. In Scriver CH, Beaudet A, Sly W, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw Hill; 1995.
34. Campistol J, Vilaseca MA, Ribes A, Riudor E. Déficit de biotinidasa. Forma de presentación y respuesta al tratamiento. An Esp Ped 1996; 44: 389-92.
35. Salbert BA, Pellock JM, Wolf B. Characterization of seizures associated with biotinidase deficiency. Neurology 1993; 43: 1351-5.
36. McVoy JR, Levy HL, Lawler M, Schmidt MA, Ebers DD, Hart PS, et al. Partial biotinidase deficiency: Clinical and biochemical features. J Pediatr 1990; 116: 78-83.
37. Taitz LS, Leonard JV, Bartlett K. Long-term auditory and visual complications of biotinidase deficiency. Early Hum Dev 1985; 11: 325-31.
38. Cole H, Weremowicz S, Morton CC, Wolf B. Localization of serum biotinidase (BTD) to human chromosome 3 in band p25. Genomics 1994; 22: 662-3.
39. Wolf B. Disorders of biotin metabolism. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. 7 Ed. The Molecular and Metabolic Bases of Inherited Disease. New York: McGraw-Hill; 1995. p. 3151-77.
40. De Vivo, Tfifiletti RR, Jacobson RI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorachia, seizures and developmental delay. N Engl J Med 1991; 325: 703-9.
41. Toone JR, Applegarth AD, Levy HL. Prenatal Dx of non-ketotic hyperglycinemia. J Inher Met Dis 1994; 17: 342-4.
42. García Silva MT. Nuevas enfermedades neurometabólicas: Signos clinicos de sospecha. Rev Neurol 1999; 28: 161-8.
43. Philippart M, Engel J Jr, Zimmerman EG. Gelastic cataplexy in Niemann-Pick disease group C and related variants without generalized sphingomyelinase deficiency. Ann Neurol 1993; 14: 492-3.
44. Tedeschi G, Bonavita S, Barton NW, Betolino A, Frank JA, Patronas NJ, et al. Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psychiatry 1998; 65: 72-9.
45. Patterson MC, Vanier MT, Suzuki K, Morris JA, Carstea E, Neufeld EB, et al. Niemann-Pick disease, type C: A lipid trafficking disorder. In Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease, 8 Ed. New York: McGraw-Hill; 2001.
46. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. Niemann-Pick disease group C: Clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 1988; 33: 331-48.
47. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000; 290: 2298-301.
48. Greer WL, Dobson MJ, Girouard GS, Byers DM, Riddell DC, Neumann PE. Mutations in NPC1 highlight a conserved NPC1 specific cysteine-rich domain. Am J Hum Genet 1999; 65: 1252-60.
49. Giraldo P, Giralt M, Pérez-Calvo JJ, Pocoví M, Roca M, Rubio-Feliu D. Enfermedad de gaucher. In Sanjurjo P, Baldellou A, eds. Errores Congénitos del Metabolismo. Madrid: Ergón; 2001.
50. Sandhoff K, Conzelmann E. The biochemical basis of gangliosidoses. Neuropediatrics 1984; 15: 85-90.
51. Campistol J, Colomer J, Póo P, Vernet A, Fernández-Álvarez E. Leucodistrofia metacromática. Forma infantil tardía. Revisión de 6 observaciones An Esp Ped 1983; 19: 41-8.
52. Mc Faul R, Cavanagh H, Lake BD, Stephens R, Whitfield AE. Metachromatic leucodystrophy: Review of 38 cases. Arch Dis Child 1982; 57: 168-75.
53. Austin JH, McAffec D, Sheares L. Metachromatic form of diffuse cerebral sclerosis. Low sulfatase activity in the urine of nine living patients with metachromatic leukodystrophy. Arch Neurol 1965; 12: 447-50.
54. Nidiffer FD, Kelly TE. Developmental and degenerative patterns associated with cognitive, behavioral and motor difficulties in Sanfilippo syndrome. An epidemiology study. J Ment Defic Res 1983; 27: 185-94.
55. Kaplan P, Wolfe LS. Sanfilippo syndrome type D. J Pediatr 1987; 110: 268-71.
56. Beaudet AL, Thomas GH. Disorders of glycoprotein degradation. In Scriver CH, Beaudet AL, Sly W, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw Hill Inc.; 1995.
57. Vamos E, Libert J, Elkhazen N, Jauniaux E, Hartun J, Wilkin P, et al. Prenatal diagnosis confirmation of infantile sialic storage disease. Prenat Diagn 1986; 6: 437-9.
58. Till JC, Roach ES, Burton BK. Sialidosis types I and II: Neuro-ophthalmic manifestation. J Clin Neuro Ophthalmol 1987; 7: 40-6.
59. Cooper A, Hatton CE, Thomley M, Sardharwalla IB. Alfa and beta mannosidosis. J Inher Metab Dis 1990; 13: 538-48.
60. Durand P, Rosanna G, Borrone G. Fucosidosis. In Durand P, O'Brien JS, eds. Genetic Errors of Glycoprotein Metabolism. Berlin: Springer-Verlag; 1982.
61. Goldfisher S, Reddy JK. Peroxisomes in cell pathology. Int Rev Exp Pathol 1984; 26: 45-84.
62. Moser HW, Moser AB. Adrenoleukodystrophy (X-Linked) in the Metabolic Basis of Inherited Diseases. In Scriver CH, Beaudet AL, Sly WS, Valle D, eds. New York: McGraw-Hill Inc.; 1995.
63. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322: 1860-6.
64. Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations. Hum Mutat 2001; 18: 499-515.
65. Campistol J, Vilaseca MA, Lambruschini N. Hiperfenilalaninemias. In Sanjurjo P, Baldellou A, eds. Errores Congénitos del Metabolismo. Madrid: Ergón; 2001.
66. Brenton DP, Tam AC, Cabrera-Abreu JC, Lilburn M. Phenylketonuria: Treatment in adolescence and adult life. Eur J Pediatr 1996; 155 (Suppl 1): S93-6.
67. Levy HL. Phenylketonuria: Old disease, new approach to treatment. Proc Natl Acad Sci U S A 1999; 96: 1811-3.
68. Scriver CR, Kaufman S. The hyperphenylalaninemias. In Scriver CR, Kaufman S, Eisensmith E, Woo SLC, Vogelstein B, Childs B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8 Ed. New York: McGraw Hill; 2001.
69. Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. J Inherit Metab Dis 1989; 12: 451-7.
70. Pietz J, Dunckelmann R, Rupp A, Rating D, Meinck HM, Schmidt H, et al. Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr 1998; 157: 824-30.
71. Blau N, Thony B, Cotton RGH, Hyland K. Disorders of tetrahydro-biopterin and related biogenic amines. In Scriver CR, Kaufman S, Eisensmith E, Woo SLC, Vogelstein B, Childs B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8 Ed. New York: McGraw Hill; 2001.
72. Weglage J, Ullrich K, Pietsch M, Funders B, Zass R, Koch HG. Untreated non-phenylketonuric-hyperphenylalaninaemia: Intellectual and neurological outcome. Eur J Pediatr 1996; 155 (Suppl 1): S26-8.
73. Guldberg P, Rey F, Zschocke J, Romano V, Francois B, Michiels L, et al. A European multicenter study of phenylalanine hydroxylase deficiency: Classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 1998; 63: 71-9.
74. Kwok SC, Ledley FD, DiLella AG, Robson KJ, Woo SL. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. Biochemistry 1985; 24: 556-61.
75. Campistol J. Errores congénitos del metabolismo intermediario en la infancia. Formas de presentación y orientación diagnóstica. Canarias Pediátrica 1997; 7: 99-106.
76. Vilaseca MA. Aminoácidos y derivados. In Fuentes Arderiu X, Castrineiros Lacambra M J, Queraltó Compañó JM, eds. Bioquímica Clínica y Patología Molecular. 2 Ed. Barcelona: Reverté SA; 1998. p. 703-19.
77. Brusilow S, Horwich A. Urea cycle enzymes. In Scriver C, Beaudet A, Sly W, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 1995.
78. Sanjurjo P, Rubio V. Diagnóstico y tratamiento de las enfermedades del ciclo de la urea. In Sanjurjo P, Baldellou A, eds. Errores Congénitos del Metabolismo. Madrid: Ergón; 2001.
79. Frezal J, Amedee-Manesme O, Mitchell G, Hevertz S, Rey J, Saudubray JM. Maple syrup urine disease: Two different forms within a single family. Hum Genet 1985; 71: 89-92.
80. Gallagher PM, Naughten E, Hanson NQ, Schwichtenberg K, Bignell M, Juan M, et al. Characterization of mutations in the cystathionine beta-synthase gene in Irish patients with homocystinuria. Molec Genet Metab 1998; 65: 298-302.
81. Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis 2001; 24: 437-47.
82. Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis 1994; 17: 383-90.
83. Mandel H, Brenner B, Berant M, Rosenberg N. Coexistence of hereditary homocystinuria and factor V Leiden: Effect on thrombosis. N Engl J Med 1996; 334: 763-8.
84. Couce ML, Fraga JM. Homocistinuria. In Sanjurjo P, Baldellou A, eds. Errores congénitos del metabolismo. Madrid: Ergón; 2001.
85. Hoffman GF, Gibson KM, Trefz KF, Nyhan WL, Bremer HJ, Bignell M, et al. Neurological manifestations of organic acid disorders. Eur J Pediatr 1994; 153 (Suppl 1): S94-100.
86. Brett J. The Organic Acidurias en Pediatric Neurology. Edimbourgh: Churchill Livingston; 1991.
87. Roth KS. Inborn errors of metabolism: The essentials of clinical diagnosis. Clin Pediatr 1991; 30: 183-90.
88. Barth PG, Hoffmann GF, Jaeken J, Lehnert W, Hanefeld F, Van Gennip AH, et al. L-2 hydroxyglutaric acidemia: A novel inherited neurometabolic disease. Ann Neurol 1992; 32: 66-71.
89. Gordon N. Pyridoxine dependency: Update. Dev Med Child Neurol 1997; 39: 63-5.
90. Wheless JW. The ketogenic diet: An effective medical therapy with side effects. J Child Neurol 2001; 16: 633-5.